Delcath, NKI-AVL enter initial launch and training agreement for CHEMOSAT system

Delcath Systems, Inc.Apr 10 2012

Delcath Systems, Inc. (NASDAQ: DCTH) announced today that the Company has entered into an initial launch and training agreement with the Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital (NKI-AVL) in Amsterdam, The Netherlands. Under the terms of the agreement, the Company will provide the NKI-AVL with logistics and clinical training support in the performance of chemosaturation therapy using the CHEMOSAT system. Training at the NKI-AVL is expected to begin in May 2012 and upon completion, the site will become the first in The Netherlands to offer Delcath's chemosaturation procedure.

Wim H. van Harten, MD, comm. Med., PhD, Director Organization and Management of the NKI-AVL, said, "The Delcath CHEMOSAT system  represents an important new option for the treatment of cancers in the liver, and we look forward to exploring its potential for a range of tumor types."

Warner Prevoo, MD Interventional Radiologist at the NKI-AVL, added, "We've been following the development of the CHEMOSAT system closely since preliminary results from the Phase 3 trial were reported at American Society of Clinical Oncology in 2010. We're pleased that we'll be among the vanguard of medical centers across Europe to begin to offer this treatment for cancers in the liver."

"We are pleased to be working with the NKI-AVL in Amsterdam to introduce CHEMOSAT into The Netherlands," said Eamonn P. Hobbs, President and CEO of Delcath Systems. With this agreement, we now have seven early launch centers in Europe and a presence in nearly all of our core target markets. The NKI-AVL is a longstanding and globally respected institution and we see this new agreement as further realization of our years of research and development."